STANDARD BIOTOOLS INC
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
LAB$0.64+2.2%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
| June 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $269,811 | $51,704 |
| Short-term investments | 124,902 | 63,191 |
| Accounts receivable, net | 32,441 | 19,660 |
| Inventory | 42,618 | 20,533 |
| Prepaid expenses and other current assets | 10,257 | 3,127 |
| Total current assets | 480,029 | 158,215 |
| Inventory, non-current | 16,252 | — |
| Royalty receivable, non-current | 3,738 | — |
| Property and equipment, net | 42,569 | 24,187 |
| Operating lease right-of-use asset, net | 31,531 | 30,663 |
| Other non-current assets | 4,282 | 2,285 |
| Acquired intangible assets, net | 24,078 | 1,400 |
| Goodwill | 106,253 | 106,317 |
| Total assets | $708,732 | $323,067 |
| LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $12,570 | $9,236 |
| Accrued liabilities | 31,929 | 21,019 |
| Operating lease liabilities, current | 5,851 | 4,323 |
| Deferred revenue, current | 15,113 | 11,607 |
| Deferred grant income, current | 3,562 | 3,612 |
| Term loan, current | — | 5,000 |
| Convertible notes, current | 54,783 | 54,530 |
| Total current liabilities | 123,808 | 109,327 |
| Convertible notes, non-current | 299 | 569 |
| Term loan, non-current | — | 3,414 |
| Deferred tax liability | 841 | 841 |
| Operating lease liabilities, non-current | 29,617 | 30,374 |
| Deferred revenue, non-current | 33,395 | 3,520 |
| Deferred grant income, non-current | 8,995 | 10,755 |
| Other non-current liabilities | 1,516 | 1,065 |
| Total liabilities | 198,471 | 159,865 |
| Commitments and contingencies (Note 8) | ||
| Mezzanine equity: | ||
| Redeemable preferred stock: $0.001 par value; zero and 256 shares authorized and issued and outstanding at June 30, 2024 and December 31, 2023, respectively; aggregate liquidation preference of zero and $255,559 at June 30, 2024 and December 31, 2023, respectively | — | 311,253 |
| Stockholders’ equity (deficit): | ||
| Preferred stock: $0.001 par value, 10,000 and 9,744 shares authorized at June 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at June 30, 2024 and December 31, 2023 | — | — |
| Common stock: $0.001 par value, 600,000 shares authorized at June 30, 2024 and 400,000 shares authorized at December 31, 2023; 389,703 and 83,364 shares issued at June 30, 2024 and December 31, 2023, respectively; 371,123 and 80,232 shares outstanding at June 30, 2024 and December 31, 2023, respectively | 389 | 83 |
| Additional paid-in capital | 1,682,480 | 860,816 |
| Accumulated other comprehensive loss | (1,500) | (2,221) |
| Accumulated deficit | (1,124,641) | (1,000,752) |
| Treasury stock at cost: 18,580 and 3,132 shares at June 30, 2024 and December 31, 2023, respectively | (46,467) | (5,977) |
| Total stockholders’ equity (deficit) | 510,261 | (148,051) |
| Total liabilities, mezzanine equity and stockholders’ equity (deficit) | $708,732 | $323,067 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.